Pacira BioSciences, Inc.
- PCRX
- NASDAQ
- Drug Manufacturers - Specialty & Generic
- Non-Opioid Pain Management
- Regenerative Health
$36.34
Quote Oct 19, 2026, 08:00 PM UTC
+47.19%over the last month
Max drawdown −3.5%From 1-month high −0.2%3 months +41.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Pacira BioSciences
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide.
Where the money comes from
Q2 2026 revenue $374.2M
- Product$190.5M50.9%
- EXPAREL$147.8M39.5%
- ZILRETTA$32.6M8.7%
- Bupivacaine Liposome Injectable Suspension$3.2M0.9%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Employees
827
Market value
$1.45B
Quote Oct 19
Floor
$36.20
0.4% below price
Resistance
$36.44
0.3% above price
Price vs analyst targets
36 analysts
Lowest target
$25.00Highest target
$36.50
$25.00Highest target
$36.50
- Price $36.34
- Average target $31.67
- Analysts' target range
The price is close to the highest analyst target. Analysts' average target sits about 13% lower.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PCRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free